Valuation Bio-Rad Laboratories, Inc.
Stocks
BIO
US0905722072
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 356.25 USD | +0.48% |
|
+7.02% | +17.58% |
| 07/08 | RBC Adjusts PT on Bio-Rad Laboratories to $390 From $370, Maintains Outperform Rating | MT |
| 05/08 | RBC Adjusts Price Target on Bio-Rad Laboratories to $370 From $320, Maintains Outperform Rating | MT |
Company Valuation: Bio-Rad Laboratories, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 22,439 | 12,460 | 9,399 | 9,182 | 8,212 | 9,428 | - | - |
| Change | - | -44.47% | -24.57% | -2.31% | -10.57% | 14.81% | - | - |
| Enterprise Value (EV) 1 | 22,439 | 11,868 | 8,992 | 8,730 | 7,874 | 8,679 | 8,463 | 8,321 |
| Change | - | -47.11% | -24.24% | -2.91% | -9.8% | 10.22% | -2.49% | -1.67% |
| P/E | 5.38x | - | -14.8x | -5.03x | 10.9x | 42.8x | 41.9x | 42.2x |
| PBR | - | 1.27x | 1.05x | 1.41x | 1.11x | 1.38x | 1.33x | - |
| PEG | - | - | - | -0x | -0x | -0.6x | 19.39x | -59.85x |
| Capitalization / Revenue | 7.68x | 4.45x | 3.52x | 3.58x | 3.18x | 3.66x | 3.58x | 3.52x |
| EV / Revenue | 7.68x | 4.24x | 3.37x | 3.4x | 3.05x | 3.37x | 3.21x | 3.1x |
| EV / EBITDA | 33.1x | 17.8x | 16.8x | 18.2x | 17.4x | 21.2x | 19.5x | 18.6x |
| EV / EBIT | 39.3x | 22.7x | 23.7x | 26.4x | 25.3x | 30.2x | 26.6x | 25.3x |
| EV / FCF | 41.9x | 127x | 24x | - | - | 28.3x | 26.8x | 25.1x |
| FCF Yield | 2.39% | 0.79% | 4.17% | - | - | 3.54% | 3.73% | 3.98% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 140.6 | - | -21.82 | -65.36 | 27.85 | 8.33 | 8.51 | 8.45 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2,923 | 2,802 | 2,671 | 2,566 | 2,583 | 2,573 | 2,633 | 2,682 |
| EBITDA 1 | 677.5 | 667.9 | 535.9 | 479.5 | 453.2 | 410.3 | 435 | 446.5 |
| EBIT 1 | 571.2 | 524 | 378.9 | 331.3 | 311.6 | 287.5 | 318.4 | 328.8 |
| Net income 1 | 4,246 | -3,628 | -637.3 | -1,844 | 759.9 | 225 | 230 | 228 |
| Net Debt 1 | - | -592.5 | -407.6 | -452.1 | -337.7 | -749 | -965.4 | -1,107 |
| Reference price 2 | 755.57 | 420.49 | 322.89 | 328.51 | 302.99 | 356.25 | 356.25 | 356.25 |
| Nbr of stocks (in thousands) | 29,918 | 29,824 | 29,145 | 27,997 | 26,975 | 26,738 | - | - |
| Announcement Date | 10/02/22 | 16/02/23 | 15/02/24 | 13/02/25 | 12/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 42.56x | 3.36x | 21.06x | -.--% | 942.8Cr | |
| 31.17x | 4.22x | 16.33x | 2.37% | 19TCr | |
| 20.26x | 3.52x | 12.36x | 3.33% | 12TCr | |
| 17.8x | 0.21x | 12.82x | 0.73% | 6.37TCr | |
| 32.06x | 8.01x | 20.38x | 1.24% | 5.51TCr | |
| 34.83x | 3.35x | 11.39x | 2.18% | 4.94TCr | |
| 35.13x | 6.18x | 19.4x | -.--% | 3.38TCr | |
| 41.87x | 1.26x | 11.45x | 0.17% | 3.07TCr | |
| 41.06x | 7.19x | 25.82x | 0.26% | 2.47TCr | |
| 20.49x | 3.09x | 11.59x | 1.43% | 2.39TCr | |
| Average | 31.72x | 4.04x | 16.26x | 1.17% | 5.97TCr | |
| Weighted average by Cap. | 28.94x | 3.95x | 15.35x | 1.85% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BIO Stock
- Valuation Bio-Rad Laboratories, Inc.
Select your edition
All financial news and data tailored to specific country editions
